Clinical Trials in Progress
The process for approving new therapies is, by design, thorough and lengthy. At any given time, Gallant has clinical trials in various phases. These trials are currently active.
We’re currently recruiting participants for a stem cell treatment in cats with feline chronic gingivostomatitis (FCGS), offering hope for cats with no alternative options.
Feline chronic gingivostomatitis is a debilitating inflammatory condition of the mouth that occurs in up to 10% of cats. It’s a painful condition that sometimes results in euthanization. Seventy percent of cats respond to full or partial mouth extraction. However, 30% don’t respond and are left with no option. Gallant is conducting a clinical trial evaluating the effectiveness of stem cell therapy in cats suffering from this condition.
If your cat has been diagnosed with FCGS or is showing signs such as excessive licking, drooling, not wanting to groom, vocalization, bleeding gums, or mouth sores, FCGS may be the problem.
We're enrolling patients in:
Mill Valley, CA
Rancho Cordova, CA
Loveland, CO
Leesburg, VA
Overland Park, KS
Rochester, MI
Nashville, TN
Davis, CA
Indianapolis, IN
Germantown, WI
York, PA
Grapevine, TX
Learn more about the study and whether your cat may be a good candidate to participate.
Feline chronic kidney disease (CKD) is the number one killer of cats. There are currently no direct interventional therapies on the market to address this serious condition. Gallant’s cellular therapy is delivered intravenously (IV) has shown promise in a feline model of CKD.
Gallant’s study of stem cell therapy for feline CKD has completed the pre-clinical phase. Stay tuned for more information as we prepare to begin the proof-of-concept phase
More than 20% of all dogs, especially older dogs, get canine osteoarthritis (OA), which can result in pain and inflammation of one or more joints.
Gallant’s stem cell therapy has demonstrated effectiveness and safety in a proof-of-concept pilot study of cells administered into the joints of dogs.
We’ve also completed phase one of the study, which evaluated the effectiveness of GP-003 administered intravenously to dogs with OA. IV administration is the easier and preferred method of administration for cell therapies that do not require a specialist to perform difficult joint injections.
Phase two is currently on-going.